Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P417: Ulcerative colitis: let’s talk about extentECCO '16 Amsterdam

Year: 2016

Authors:

A. Vaz*, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro

Centro Hospitalar do Algarve, Faro, Portugal

P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitisECCO '16 Amsterdam

Year: 2016

Authors:

P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P419: Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodiesECCO '16 Amsterdam

Year: 2016

Authors:

C. Höög*, M. Eberhardson, S. Almer

Karolinska Institute, Stockholm, Sweden

P420: Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?ECCO '16 Amsterdam

Year: 2016

Authors:

D. Klett*, D. Strobel, D. Wildner, R. Atreya, M. F. Neurath, R. S. Görtz

Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany

P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseasesECCO '16 Amsterdam

Year: 2016

Authors:

K. Juzlova¹, K. Koblova¹, J. Herzogova¹, M. Bortlik*², D. Duricova², M. Lukas²

¹2nd Faculty of Medicine, Charles University, Department of Dermatovenereology, Prague, Czech Republic, ²Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic

P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapyECCO '16 Amsterdam

Year: 2016

Authors:

J. W. Lee, C. H. Choi*

Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea

P423: Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumabECCO '16 Amsterdam

Year: 2016

Authors:

C. Olbjørn*^{1, 2}, J. B. Rove¹, J. Jahnsen^{2, 3}

¹Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway, ²University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ³Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway

P424: Surgery for children with Crohn’s disease.ECCO '16 Amsterdam

Year: 2016

Authors:

M. Stefanowicz*¹, H. Ismail¹, G. Kowalewski¹, A. Kowalski¹, J. Kierkuś², P. Kaliciński¹

¹Children’s Memorial Health Institute, Department of Paediatric Surgery and Organ Transplantations, Warszawa, Poland, ²Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warszawa, Poland

P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvementsECCO '16 Amsterdam

Year: 2016

Authors:

A. Franceschetti*¹, A. Baskett², H. McKenzie²

¹Ipsos healthcare, London, United Kingdom, ²Ipsos Healthcare, London, United Kingdom

P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

E. Zittan*^{1, 2}, O. B. Kelly¹, B. Kabakchiev¹, G. C. Nguyen¹, K. Croitoru¹, A. H. Steinhart¹, M. S. Silverberg¹

¹Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada, ²Institute of Gastroenterology and Liver Diseases, Emek Medical Centre, Afula, Israel

P427: The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

A. Amiot*¹, J. C. Grimaud², X. Treton³, J. Filippi⁴, B. Pariente⁵, L. Peyrin-Biroulet⁶, A. Noureille⁷, A. Buisson⁸, F. Carbonnel⁹, A. Bourrier¹⁰, S. Nancey¹¹, X. Roblin¹², P. Marteau¹³, R. Altwegg¹⁴, J. Moreau¹⁵, A. Aubourg¹⁶, G. Savoye¹⁷, A. L. Pelletier¹⁸, M. Fumery¹⁹, B. Bonaz²⁰, Y. Bouhnik³

¹Henri Mondor Hospital, Gastroenterology, Creteil, France, ²Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, ³APHP Beaujon, Department of Gastroenterology, Clichy, France, ⁴Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁵CHRU Lille, Department of Gastroenterology, Lille, France, ⁶CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, ⁷CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ⁸CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ⁹CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, ¹⁰APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, ¹¹Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, ¹²University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, ¹³Hospital Lariboisière, Department of Gastroenterology, Paris, France, ¹⁴CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ¹⁵CHU de Toulouse Hospital de Rangueil, Department of Gastroenterology, Toulouse, France, ¹⁶Chu Tours, Department of Gastroenterology and Hepatology, Tours, France, ¹⁷CHU Rouen, Department of Gastroenterology, Rouen, France, ¹⁸Hospital Bichat Claude Bernard, Department of Gastroenterology, Paris, France, ¹⁹Amiens University Hospital, Department of Gastroenterology, Amiens, France, ²⁰Grenoble, gastroenterologie, Grenoble, France

P428: Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studiesECCO '16 Amsterdam

Year: 2016

Authors:

A. Mukherjee¹, C. Deng², R. Xie², S.W. Martin³, G. Chan⁴, M. Moscariello⁴, W. Niezychowski⁴, E. Maller*⁴

¹Pfizer Inc, Groton, United States, ²Pfizer Inc, Shanghai, China, ³Pfizer Inc, Cambridge, United States, ⁴Pfizer Inc, Collegeville, Pennsylvania, United States

P429: The effects of psychiatric treatment in patients with inflammatory bowel disease: a prospective studyECCO '16 Amsterdam

Year: 2016

Authors:

O. Yanartas¹, H. c. T. Kanı², E. Bicakci³, Y. Bez¹, M. Banzragch³, Z. Senkal¹, I. Kilic⁴, O. Atug³, K. Kuscu¹, N. Imeryuz³, H. Akin*³

¹Marmara University, Psychiatry, Istanbul, Turkey, ²Marmara University, Internal Medicine, Istanbul, Turkey, ³Marmara University, Gastroenterology, Istanbul, Turkey, ⁴Marmara University, Medical Student, Istanbul, Turkey

P430: Prognostic significance of serial faecal calprotectin in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

Y. Zhulina¹, Y. Cao², K. Amcoff³, M. Carlson³, C. Tysk¹, J. Halfvarson*¹

¹Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ²Örebro University, Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, ³Uppsala University, Department of Medical sciences, Gastroenterology Research Group, Uppsala, Sweden

P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patientsECCO '16 Amsterdam

Year: 2016

Authors:

T. Ogashiwa*¹, M. Murakami¹, S. Tsuda¹, M. Nishio¹, Y. Kogure¹, K. Kasahara¹, K. Hirai², Y. Fukuno², M. Jin², A. Hanzawa², H. Yonezawa², K. Numata³, H. Kimura¹, R. Kunisaki¹

¹Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, ²Yokohama City University Medical Centre, Department of Laboratory Medicine and Clinical Investigation, Yokohama, Japan, ³Yokohama City University Medical Centre, Gastroenterology Centre, Yokohama, Japan

P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations surveyECCO '16 Amsterdam

Year: 2016

Authors:

L. Peyrin-Biroulet*¹, S. Lönnfors², S. Danese³, X. Roblin⁴, L. Avedano⁵, M. Greco⁵

¹University Hospital of Nancy, Department of Gastroenterology, Nancy, France, ²European Federation of Crohn’s and Ulcerative Colitis Associations, Medical Writer, Brussels, Belgium, ³Humanitas University, Department of Gastroenterology, Milan, Italy, ⁴Saint-Étienne University Hospital, Gastroenterology and Hepatology, Saint-Étienne, France, ⁵European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium

P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

G. Attara*¹, R. Bailey², B. Bressler³, J. Marshall⁴, R. Panaccione⁵, G. Aumais⁶

¹Gastrointestinal Society, Vancouver, Canada, ²University of Alberta, Zeidler Ledcor Centre, Department of Medicine, Division of Gastroenterology, Edmonton, Canada, ³University of British Columbia, Medicine, Division of Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, ⁴McMaster University Medical Centre, Department of Gastroenterology, Hamilton, Canada, ⁵University of Calgary, Department of Gastroenterology, Foothills Medical Centre, Calgary, Canada, ⁶CHUM Centre Hospitalier de l’Université de Montréal, Hôpital Maisonneuve-Rosemont, Medicine, Montréal, Canada